Seneque Revenue and Competitors
Estimated Revenue & Valuation
- Seneque's estimated annual revenue is currently $6.2M per year.
- Seneque's estimated revenue per employee is $155,000
Employee Data
- Seneque has 40 Employees.
Seneque's People
Name | Title | Email/Phone |
---|
Seneque Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Seneque?
Seneque is a life sciences company that brings together leading cellular scientists to advance the frontiers of health and longevity. We transform breakthroughs in cellular science into consumer solutions that enhance healthspan, lifespan and vitality. Our portfolio of science-based consumer health brands use natural molecules to optimize the body's NAD+ metabolism. Our international research platform is undertaking an extensive in-human research program that is propelling development of our proprietary NMN-C® and other synergetic molecules as NAD+ boosters to support cardiovascular, cognitive, muscular and immune health.
keywords:N/AN/A
Total Funding
40
Number of Employees
$6.2M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Seneque News
De Sénèque, matrice des vers raciniens. Une tragédie qui vient de si loin où tout est fureur, animalité, vertige des sens, fascination pour...
Born January 24, 1935 in Angouleme, France, she was the daughter of the late René Jean and Marguerite (Seneque) Bourzeix.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.1M | 40 | 8% | N/A |
#2 | N/A | 41 | 8% | N/A |
#3 | $8.1M | 41 | N/A | N/A |
#4 | $6.4M | 41 | N/A | N/A |
#5 | $11.9M | 42 | 40% | N/A |